Type Public limited company Industry Pharmaceuticals Operating income Headquarters United Kingdom Chief business officer David Hipkiss | Traded as LSE: CIR Founded 2006 CEO Steve Harris Revenue 10.8 million GBP (2015) | |
 | ||
Key people Francesco Granata, (Chairman)
Steven Harris, (CEO) Stock price CIR (LON) 86.19 GBX +1.19 (+1.40%)3 Mar, 5:01 PM GMT - Disclaimer | ||
Circassia Pharmaceuticals is a specialty biopharmaceutical company developing a range of immunotherapies. It is listed on the London Stock Exchange.
Contents
History
The company was founded by Steve Harris and Charles Swingland in 2006. It was the subject of an Initial Public Offering in March 2014.
Operations
The company's technology, ToleroMune, was initially developed by scientists at Imperial College London. The company is in the process of developing a treatment for cat allergies.
References
Circassia Pharmaceuticals Wikipedia(Text) CC BY-SA